Cyprus neurology and genetics institute with strong bioinformatics capacity, specializing in genomic medicine for haematological and neurological disorders.
The Cyprus Institute of Neurology and Genetics (CING) is a national research centre and tertiary hospital specializing in neurological and genetic disorders. Their research spans bioinformatics, genomics, haematological diseases, and personalized medicine, with particular strength in translating multi-omics data into clinical applications. They serve as Cyprus's primary hub for genetics research and have invested heavily in building bioinformatics infrastructure and training capacity. Beyond neurology and genetics, they contribute computational and genomic expertise to projects ranging from agricultural genomics to paediatric drug development.
BIORISE established an ERA Chair in bioinformatics; GenoMed4ALL applies multi-omics and federated learning; ELIXIR-CONVERGE contributes to FAIR data infrastructure; AGRICYGEN extended genomics to agriculture.
GenoMed4ALL focuses on genomics-driven personalized medicine for haematological diseases; ARISE addresses sickle cell disease epidemiology and prevention across Africa.
ELIXIR-CONVERGE builds sustainable FAIR life-science data services; BIORISE established lasting bioinformatics infrastructure at CING.
AGRICYGEN covered small ruminant genomics, plant genomics and phenomics, and microbial metagenomics for agricultural applications in Cyprus.
STIMULATE involved computational fluid dynamics, lattice QCD, and molecular dynamics simulations in multiscale biological and physical systems.
ID-EPTRI contributed to designing a European infrastructure for paediatric drug development.
In the early period (2015–2018), CING focused on capacity building — establishing bioinformatics infrastructure (BIORISE ERA Chair), expanding into agricultural genomics (AGRICYGEN), and positioning itself within precision medicine networks (IPMT). From 2019 onward, the institute shifted toward applied clinical genomics and data-driven medicine: sickle cell disease research (ARISE), FAIR data stewardship (ELIXIR-CONVERGE), and AI-powered personalized haematology (GenoMed4ALL with federated learning). The trajectory shows a clear move from building foundational genomics capacity to deploying that capacity on specific disease challenges using advanced computational methods.
CING is converging on AI-assisted personalized medicine for blood disorders, combining their bioinformatics infrastructure with federated learning and multi-omics — expect them to seek partners in clinical AI, rare disease registries, and health data spaces.
CING primarily participates in consortia rather than leading them, having coordinated only 2 of 9 projects — both focused on building internal capacity (BIORISE, GENEVA). They operate comfortably in large multinational consortia, with 145 unique partners across 35 countries indicating broad connectivity rather than a small trusted circle. This makes them an accessible partner: they are experienced at contributing specialized genomics and bioinformatics expertise within larger teams and are well-practised in cross-border collaboration despite being a relatively small institution.
Remarkably wide network for a Cyprus-based institute — 145 unique partners spanning 35 countries, reflecting participation in large pan-European and even Africa-focused consortia (ARISE). Their partnerships reach well beyond the Eastern Mediterranean, covering most of the EU and extending to global health networks.
CING is one of the few institutions in the Eastern Mediterranean that combines clinical genetics expertise with dedicated bioinformatics infrastructure built through an ERA Chair investment. For consortium builders, they offer a rare combination: a Widening Country partner that brings genuine genomics and data science capability rather than just geographic coverage. Their dual identity as both a research centre and a tertiary hospital means they can bridge basic genomics research and clinical application in ways that purely academic groups cannot.
